DKTK Tübingen

€2.5 million for developing a novel cancer immunotherapy

Scientists from the German Cancer Consortium (DKTK) at Tübingen University Hospital have developed a promising bispecific antibody for use in immunotherapy of prostate cancer and so-called squamous cell carcinoma, which can occur, for example, in the lungs, skin or uterus. The antibody binds to cancer cells as well as immune cells, thus provoking an immune response against the tumor. The Helmholtz Association now provides €2.5 million from its validation fund for the purpose of executing the next steps in the pharmaceutical development of the bispecific antibody.In the German Cancer Consortium (DKTK), the German Cancer Research Center (DKFZ) in Heidelberg joins up as a core center in long-term collaborations with university institutes and hospitals all over Germany that are specialized in research and treatment with a focus on oncology.

30 Years of the Cancer Information Service

More important than ever before!

Every year, more and more people are afflicted by cancer. In 2015 there were about 490,000 new cases in Germany alone. So, it is not surprising that the need for reliable information continues to grow: Last year, the German Cancer Information Service (KID) of the German Cancer Research Center (DKFZ) responded to 34,000 individual enquiries from all across Germany – more than ever before. Every month between 450,000 and 635,000 users accessed information on the website Since 2014, doctors, caregivers, therapists and psychological counselors have utilized and valued the professional service

World Pancreatic Cancer Day 2016

Research to combat pancreatic cancer

Cancer of the pancreas is one of the most aggressive types of cancer and therapies currently used are usually rather ineffective. Therefore, scientists at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) in Heidelberg are very committed in the fight against this disease. They discovered what makes this cancer type so resistant against drugs and why the tumors spread outside the pancreas so early. Based on these findings, they are testing schizophrenia medications, novel agents and even viruses in the treatment of pancreatic cancer.

We are asking for your support

Your Donation for Cancer Research
Deadline 5th January 2017

Apply now for the International PhD Program at the DKFZ!

Are you looking for excellent research opportunities for your PhD studies at the forefront of basic, epidemiological or translational cancer research? Apply here!

DKTK Berlin

Boost for cancer therapies with tumors grown in petri-dish

Cancer can be caused by a variety of genetic mutations. One challenge medicine faces is finding tailor-made treatment for each patient based on their individual genetic differences. Scientists at the German Cancer Consortium (DKTK) at the Charité Comprehensive Cancer Center in Berlin have now received 2.6 million Euros so, together with regional biotechnology companies, they can make test systems available for personalized medication screening. The German Cancer Consortium (DKTK) builds a strong, long-term, institutional structure between the German Cancer Research Center (DKFZ) and universities and university hospitals all over Germany specially designated to clinical oriented cancer research.


Search for research topic

Breast cancer month October

Breast cancer month October: Information can help reduce fears

Current studies show that patients with breast cancer benefit from reliable health information and education, reducing their fears and worries and improving their quality of life. The cancer information hotline (Krebsinformationsdienst, KID) at the German Cancer Research Center (DKFZ) in Heidelberg has been informing patients and their families for 30 years about all questions regarding cancer. In 50% of all enquiries on tumor localization, the subject of breast cancer is paramount.

Latest News

Gene fusion opens up treatment possibilities for aggressive brain cancer

Glioblastoma, an extremely aggressive type of brain cancer, is still mostly untreatable in children. Scientists from the German Cancer Research Center (DKFZ), Heidelberg University Hospital and an international consortium including the Max Planck Institute for Molecular Genetics (MPIMG) undertook a comprehensive analysis of glioblastoma genomes. In about ten percent of the cases, they found a previously unknown mutation that is treatable with a targeted drug that has already been approved. In experiments with mice, the investigators successfully used this agent to halt the growth of brain tumors with this mutation.

Latest News

No billboard advertising of tobacco products - for the protection of minors

Germany is the only European country still allowing unrestricted advertising of tobacco products on large billboards. This type of advertising deliberately targets young consumers. A current publication by the German Cancer Research Center (DKFZ) shows that two thirds of adolescents and young adults are consciously aware of billboard advertising, and are thereby encouraged to start smoking. At the same time, a current survey suggests that the majority of the population supports a ban of billboard advertisement for tobacco products.

DKFZ - A Video

Research For A Life Without Cancer
to top